AC Immune (ACIU) Accumulated Expenses (2015 - 2026)

AC Immune (ACIU) has 12 years of Accumulated Expenses data on file, last reported at $8.3 billion in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 66535.86% year-over-year to $8.3 billion in Q1 2026; TTM through Mar 2026 was $8.3 billion, a 66535.86% increase from a year earlier, with the FY2025 full-year figure at $9.7 billion, up 70354.35% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $8.3 billion, down from $10.1 billion in the prior quarter.
• Over the last five years, Accumulated Expenses for ACIU reached as high as $12.5 billion in Q4 2023 and fell as low as $9.4 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $3.1 billion across 5 years, with a median of $13.8 million in 2024.
• Across the five-year window, Accumulated Expenses sank 99.95% in 2022 and surged 127766.11% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $9.8 million in 2022, then jumped by 127766.11% to $12.5 billion in 2023, then sank by 99.89% to $13.8 million in 2024, then soared by 72985.38% to $10.1 billion in 2025, then dropped by 18.15% to $8.3 billion in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $8.3 billion in Q1 2026, $10.1 billion in Q4 2025, and $15.0 million in Q3 2025.